As expected, the European Commission approves AbbVie's (NYSE:ABBV) SKYRIZI (risankizumab), an IL-23 inhibitor, for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. In early March, the advisory group CHMP adopted a positive opinion backing approval.
The FDA approved the med last week.
Shares are up a fraction premarket.
Subscribe for full text news in your inbox